J&J Gets FDA OK for Pediatric Uses of Simponi Aria
September 30 2020 - 9:55AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on
Wednesday said the U.S. Food and Drug Administration approved
expanded pediatric use of its inflammatory disease drug Simponi
Aria.
The company said the agency approved Simponi Aria for patients
two years of age and older for the treatment of active
polyarticular juvenile idiopathic arthritis and has extended the
drug's active psoriatic arthritis indication for the same patient
population.
Simponi Aria was already approved in the U.S. for adults with
moderately to severely active rheumatoid arthritis, active
psoriatic arthritis and active ankylosing spondylitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 30, 2020 09:40 ET (13:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
